北京神州细胞生物技术集团股份公司 2024 年度 审计报告 | 索引 | 项码 | | --- | --- | | 审计报告 | 1-5 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-98 | 事务所| 北京市东城区朝阳门北大街 8 号宫华大厦 A 座 9 层 胜系曲话· 9/F Block A. Fu Hua Mansion No 8 Chaovangmen Beidaiie Donacheng District. Beijing 100027. P.R.China +86 (010) 6554 7190 审计报告 XYZH/2025BJAA1B0445 北京神州细胞生物技术集团股份公司 北京神州细胞生物技术集团股份公司全体股东: 一、审计意见 我们审计了北京神州细胞生物技术集团股份公司(以下简称神州细胞公司)财务 ...

1、 专项审计报告 2、 附表 北京神州细胞生物技术集团股份公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 关于北京神州细胞生物技术集团股份公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 委托单位：北京神州细胞生物技术集团股份公司 审计单位：信永中和会计师事务所（特殊普通合伙） | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | | 联系电话: 北京市东城区朝阳门北大街 官永中和会计师事务所 telephone: 8 号富华大厦 A 座 9 层 9/F, Block A, Fu Hua Mansion No.8, Chaoyangmen Beidajie, Dongcheng District, Beijing, 100027, P.R.China ShineWing 传真: +86 (010) 6554 2288 关于北京神州细胞生物技术集团股份公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025BJAA1B0441 北京神州细胞生物技术集团股 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥519.74 million, a decrease of 15.15% compared to ¥612.50 million in the same period last year[4] - Net profit attributable to shareholders was ¥63.77 million, down 14.06% from ¥74.20 million year-on-year[4] - The net profit after deducting non-recurring gains and losses dropped significantly by 84.98%, from ¥157.00 million to ¥23.58 million[4] - The net cash flow from operating activities was negative at -¥106.92 million, a decline of 161.23% compared to ¥174.61 million in the previous year[4] - Total operating revenue for Q1 2025 was CNY 519.74 million, a decrease of 15.1% compared to CNY 612.50 million in Q1 2024[17] - Net profit for Q1 2025 was CNY 63.94 million, down 14.0% from CNY 74.41 million in Q1 2024[18] - The company recorded a total profit of CNY 63.94 million in Q1 2025, with no income tax expenses reported[18] Research and Development - R&D investment totaled ¥185.37 million, representing a decrease of 24.18% from ¥244.48 million year-on-year[4] - R&D expenses accounted for 35.67% of operating revenue, down from 39.92% in the previous year[5] - Research and development expenses were CNY 177.81 million in Q1 2025, a decrease of 25.1% from CNY 237.33 million in Q1 2024[17] - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing product efficiency[22] Assets and Liabilities - Total assets increased by 5.04% to ¥3.45 billion from ¥3.28 billion at the end of the previous year[5] - Current assets totaled RMB 1,611,064,341.24, up from RMB 1,460,622,848.37, indicating an increase of about 10.27%[14] - Total liabilities reached RMB 3,251,127,937.15, compared to RMB 3,149,055,574.41, reflecting an increase of approximately 3.25%[15] - The company's short-term borrowings rose to RMB 1,235,413,267.58 from RMB 1,077,987,553.63, indicating an increase of about 14.61%[14] - Non-current assets totaled RMB 1,838,541,502.94, slightly up from RMB 1,823,373,569.25, showing a marginal increase of about 0.83%[14] - The cash and cash equivalents decreased to RMB 302,866,339.99 from RMB 314,933,923.79, reflecting a decline of about 3.54%[12] Shareholder Information - Shareholders' equity attributable to shareholders rose by 44.97% to ¥204.26 million from ¥140.90 million at the end of the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 11,178[8] - The company reported a decrease in retained earnings, with a balance of RMB -3,759,707,359.98 compared to RMB -3,818,000,173.03, indicating an improvement in the negative retained earnings by approximately 1.54%[15] Market Outlook and Strategy - The company provided a future outlook, projecting a revenue growth of 20% for the full year 2025[22] - New product launches are expected to contribute an additional 300 million RMB in revenue by Q3 2025[22] - Market expansion plans include entering two new international markets by the end of 2025[22] - The company is considering strategic acquisitions to enhance its market position, with a budget of 200 million RMB allocated for potential deals[22] - A new marketing strategy is set to increase brand awareness, targeting a 30% increase in customer engagement by Q4 2025[22] Operational Efficiency - The company aims to reduce operational costs by 10% through efficiency improvements in the next fiscal year[22] - The gross margin improved to 45%, up from 40% in the previous year[22] - The company experienced a significant decrease in cash inflow from sales, which was CNY 420.11 million in Q1 2025, down 32.9% from CNY 626.38 million in Q1 2024[20]

Financial Performance - The company achieved a total operating revenue of 2,512.71 million yuan, representing a year-on-year growth of 33.13%[3]. - The net profit attributable to shareholders of the listed company was 111.95 million yuan, with a net profit of 474.41 million yuan after deducting non-recurring gains and losses[3]. - The company's operating revenue for 2024 reached ¥2,512,708,141.32, representing a 33.13% increase compared to ¥1,887,349,306.40 in 2023[25]. - The net profit attributable to shareholders was ¥111,951,088.88 in 2024, a significant turnaround from a loss of ¥396,018,311.08 in 2023[25]. - The net cash flow from operating activities improved to ¥125,123,630.31 in 2024, compared to a negative cash flow of ¥383,369,058.67 in 2023[26]. - The company's total assets increased by 20.80% to ¥3,283,996,417.62 at the end of 2024, up from ¥2,718,536,171.39 in 2023[26]. - Basic earnings per share for 2024 were ¥0.24, a recovery from a loss of ¥0.89 per share in 2023[27]. - The net assets attributable to shareholders turned positive, reaching ¥140,896,888.73 at the end of 2024, compared to a negative net asset of ¥599,461,618.33 at the end of 2023[28]. - The company reported a total of ¥90,084,460.16 in government subsidies related to its normal business operations in 2024[33]. - The total non-recurring losses amounted to ¥362,459,499.73 in 2024, compared to ¥332,337,823.28 in 2023, indicating ongoing challenges in non-operational areas[33]. Research and Development - The company is in the process of developing new products, including the PD-1 monoclonal antibody drug and the CD20 monoclonal antibody drug[13]. - The company's total R&D investment for 2024 was 936.02 million yuan, focusing on clinical research for multiple products[39]. - The company obtained 16 new invention patent applications and 82 new invention patent authorizations during the reporting period[39]. - The company has established a high-efficiency, high-throughput technology platform for the research and production of biopharmaceuticals, with multiple products in various stages of clinical research[51]. - The company has developed a new series of recombinant protein vaccines for COVID-19 variants, with several products included in emergency use by the state[60]. - The company has multiple products in various clinical stages, including SCT650C for moderate to severe plaque psoriasis, which has initiated Phase II clinical trials[66]. - The company is conducting post-marketing clinical research for SCT800, a third-generation recombinant coagulation factor product, with a total investment of ¥25 million[103]. - The company has developed SCT1000, the world's first 14-valent HPV vaccine, which has completed Phase III clinical trials and shows promising immunogenicity and safety[84]. - The company has rapidly completed the preclinical development and production of 6 COVID-19 neutralizing antibodies and 10 recombinant protein vaccines since early 2020, demonstrating advanced R&D speed and efficiency[91]. Product Development and Market Strategy - The core product Anjain® had stable sales, reaching 1.89 billion yuan, an increase of 6.18% year-on-year[37]. - The sales revenue of three antibody products, including Anpingxi®, Anjairun®, and Anbeizhu®, exceeded 620 million yuan, a significant increase of 499.80%[37]. - The company successfully launched the drug Anyouping® for head and neck squamous cell carcinoma, expanding its product matrix in oncology[37]. - The company has signed agreements with over ten "Belt and Road" countries, including Indonesia and Brazil, to commercialize its product Anjain®[46]. - The company has submitted drug registration applications for Anjain® in Thailand and the Philippines, with approvals expected in December 2024 and March 2025 for Pakistan and Indonesia, respectively[46]. - The company has accelerated cooperation with "Belt and Road" countries for its biosimilar drugs Anjairun® and Anbeizhu®, with Anjairun®'s registration application submitted in Pakistan in September 2024 and approval expected in February 2025[47]. - The company is actively enhancing its compliance operations to mitigate legal and reputational risks, ensuring adherence to domestic and international regulations[48]. - The company is focused on developing treatments for malignant tumors, autoimmune diseases, infectious diseases, and genetic disorders[158]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[5]. - The company has not disclosed any special arrangements for corporate governance or other significant matters[9]. - The company emphasizes that forward-looking statements regarding its planning and development strategies do not constitute substantive commitments to investors[7]. - The company has a diverse board with independent directors and various management roles, ensuring governance compliance[185]. - The company has established specialized committees to enhance governance and oversight functions[199]. - The audit committee approved the annual financial report for 2023 and the budget for 2024, all with unanimous votes[200]. - The company has not faced any penalties from securities regulatory agencies in the past three years[196]. Market and Industry Trends - The global pharmaceutical market is projected to grow from $1,100.2 billion in 2015 to $1,569.5 billion in 2023, with a compound annual growth rate (CAGR) of 8.6% for biopharmaceuticals, outpacing the 3.5% CAGR for chemical drugs[73]. - The Chinese biopharmaceutical market size reached approximately RMB 1.8 trillion in 2023, with a compound annual growth rate (CAGR) of 14.4% for biological drugs from 2015 to 2023, significantly outpacing the 2.1% CAGR for chemical drugs[74]. - The Chinese human vaccine market grew from RMB 53.5 billion in 2019 to RMB 120.5 billion in 2023, representing a CAGR of 22.5%, and is expected to reach RMB 343.1 billion by 2032, with a projected CAGR of 12.3% from 2023 to 2032[76]. - The overall success rate for biological drugs from Phase I clinical trials to commercialization is 11.5%, compared to 6.2% for chemical drugs, indicating a higher clinical success rate for innovative biological products[78]. - The integration of AI technology is transforming various stages of biopharmaceutical R&D, indicating a shift towards more advanced and efficient development processes[75]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[4]. - The company is actively enhancing its risk management system to address macroeconomic risks, including geopolitical tensions and trade frictions, which may impact international business operations[127]. - The company faces operational risks related to insufficient working capital due to ongoing R&D investments and potential challenges in equity and debt financing[124]. - The company acknowledges the competitive landscape in the biopharmaceutical industry, necessitating continuous innovation and technology tracking[119]. - The company faces risks of significant revenue decline or losses due to market competition and the performance of newly launched products[115]. Future Outlook - The company plans to strengthen its international strategy and supply chain resilience to better compete in the global market for innovative drugs[87]. - The company anticipates achieving profitability in 2024 through cost control and improved R&D efficiency[129]. - The company plans to continue investing in R&D and enhancing market promotion for existing products, which may lead to uncertainties in future revenue growth[113]. - The company aims to improve operational efficiency through enhanced internal controls and financial management practices[186]. - The company plans to implement a "quality improvement and efficiency return" action plan for 2024[197].

北京神州细胞生物技 北京神州细胞生物技术集团股份公司 第二届董事会提名与薪酬委员会 关于独立董事候选人任职资格的审查意见 根据《中华人民共和国公司法》(以下简称"《公司法》")、《上市公司独立董 事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第1号 -- 规范运作》等法律法规、规范性文件以及《北京 神州细胞生物技术集团股份公司章程》(以下简称"《公司章程》")等相关规定, 北京神州细胞生物技术集团股份公司(以下简称"公司")第二届董事会提名与 薪酬委员会对拟提交第二届董事会第十五次会议审议的《关于公司董事会换届暨 选举第三届董事会独立董事候选人的议案》进行了认真的审阅,对独立董事候选 人的履历等相关资料进行了审核,出具审查意见如下: 独立董事候选人贾凌云女士、张学先生、王浩峰先生均具备丰富的专业知识, 其教育背景、工作经历、业务能力符合公司独立董事任职要求。其中,王浩峰先 生为会计专业人士,具备注册会计师资格。上述三位独立董事候选人均未持有公 司股份,与公司控股股东、实际控制人、持有公司 5%以上股份的股东及其他董 事、监事、高级管理人员之间不存在关联关系,不存在 ...

北京神州细胞生物技术集团股份公司 2024年度独立董事述职报告 一、独立董事个人基本情况 本人苏志国,1954年出生,中国国籍,最高学历和学位:博士,毕业时间和 院校:1985年12月毕业于英国曼彻斯特大学。工作经历:1986年1月至1987年1月 荷兰德尔夫特大学博士后:1987年2月至1997年11月大连理工大学讲师(87年)、 副教授(88年)、教授(91年):1997年11月至2019年9月中国科学院过程工程 研究所研究员;2019年9月退休,以退休返聘身份任中国科学院过程工程研究所 国家生化工程技术研究中心副主任兼首席科学家。专业背景为生物工程科学与技 术,曾任生化工程国家重点实验室主任。 自2019年3月17日起担任北京神州细胞生物技术集团股份公司本届董事会独 立董事,2022年担任第二届董事会独立董事。本人在董事会任职提名与薪酬委员 会主任委员,并任职战略委员会委员。 (苏州)有限公司、中科森辉(德州)生物科技有限公司、中科鼎辉生物科技(苏 州)有限公司董事长。 关于是否存在影响独立性的情况说明 本人及直系亲属均不持有北京神州细胞生物技术集团股份公司(以下简称 "神州细胞")及其相关关联公司的股 ...

2019年3月17日,公司第一届董事会及董事会专门委员会成员经公司创立大 会选举产生,苏志国先生、王晓川先生、何为先生当选公司独立董事,任期三年。 2022年5月17日,公司召开2021年年度股东大会,选举产生了公司第二届董事会 董事,苏志国先生、何为先生和我本人当选,继续担任公司独立董事,任期三年。 何为先生、我本人同时当选董事会审计委员会委员,何为先生为审计委员会主任 委员。苏志国先生、我本人同时当选董事会提名与薪酬委员会委员,苏志国先生 为提名与薪酬委员会主任委员。苏志国先生、我本人同时当选董事会战略委员会 委员。 (一) 个人履历 王晓川:现任公司独立董事,1955年出生,1982年7月毕业于吉林大学法律 系,硕士学位。1982年8月至2020年5月历任对外经济贸易大学教师、教授、博士 研究生导师;1996年7月至今作兼职律师工作。 (二)是否存在影响独立性的情况说明 北京神州细胞生物技术集团股份公司 2024年度独立董事述职报告 作为北京神州细胞生物技术集团股份公司(以下简称"公司")的独立董事, 2024年我严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上海 证券交易所科创板股票上市规 ...

(一)个人履历 何为. 男,1974年出生,中国国籍,1999年6月毕业于中南财经大学,经济 学硕士学位。1999年9月至2002年6月任招商证券股份有限公司高级经理;2002年 6月至2016年10月任深圳证券交易所执行经理;2016年10月至2017年5月任北京和 易瑞盛资产管理有限公司副总经理;2018年10月至今任立信会计师事务所(特殊 普通合伙) 合伙人。 本人何为,作为会计专业人士,在董事会审计委员会担任主任委员。 北京神州细胞生物技术集团股份公司 2024年度独立董事述职报告 一、独立董事基本情况 公司第二届董事会共9名董事,其中独立董事3名,分别为苏志国先生、王晓 川先生、何为先生,占董事会人数三分之一,符合相关法律法规及公司制度的规 定。 2024年度,本人作为北京神州细胞生物技术集团股份公司(以下简称"公司") 的独立董事,严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第1号 -- 规范运作》等法律法规,勤勉尽责、独立履职,及时关注公司经 营发展,积极出席相关会议,认真审议董事会各项议案,并对重大事 ...

北京神州细胞生物技术集团股份公司 董事会议事规则 第一条 宗旨 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和董事会有 效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司治理准则》《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）等法律法规、规范性文件和 《北京神州细胞生物技术集团股份公司章程》（以下简称"《公司章程》"）的规 定，制定本规则。 第二条 证券部 董事会下设证券部，处理董事会日常事务。 董事会秘书兼任证券部负责人，保管董事会和证券部印章。 第三条 定期会议 董事会会议分为定期会议和临时会议。 董事会每年至少召开两次定期会议，并应根据《公司章程》或者本规则规定 召开临时会议。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，证券部应当充分征求各董事的意见， 初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总经理和其他高级管理人员的意见。 第五条 临时会议 1 有下列情形之一的，董事会应当召开临时会议： 第六条 临时会议的提议程序 第七条 会议的召集和主持 董事会会议由董事长召集 ...